Ginkgo Bioworks Intrinsic Value – Gingko Bioworks and Synplogen Partner to Bring Gene Therapy to Japan
December 7, 2023
🌥️Trending News
GINKGO ($NYSE:DNA): Gingko Bioworks and Synplogen have recently partnered in order to bring gene therapy services to Japan. Gingko Bioworks is a leading life sciences company that specializes in engineering biology. The company uses its proprietary software and hardware platform to design, build, and test biological systems for a variety of applications, such as drug development, agriculture, diagnostics, and more. Synplogen is a Japanese biopharmaceutical company dedicated to providing innovative therapies and treatments that address unmet medical needs.
The company has extensive experience in gene therapy research and has already developed a number of gene therapies for various diseases. Through their collaboration with Gingko Bioworks, Synplogen will be able to expand their gene therapy capabilities to a wider population. This partnership will help bring the latest gene therapy technology to Japan and make it accessible to people who need it.
Price History
This news saw the company’s stock open on Wednesday at $1.4 and close at $1.3. The partnership between GINKGO BIOWORKS and Synplogen will bring the best of their respective knowledge and expertise to the development of gene therapies in Japan. GINKGO BIOWORKS will be contributing its advanced biomanufacturing technology to the partnership, while Synplogen will be providing its experience in gene therapies and clinical development.
Both companies are committed to providing the highest quality gene therapies to the Japanese market. This partnership is expected to bring improved treatments to those in need of gene therapy in the region. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 314.99 | -859.79 | -232.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -342.2 | -4.28 | 95.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.03k | 773.71 | 0.59 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -232.8% |
| FCF Margin | ROE | ROA |
| -128.6% | -33.3% | -22.6% |
Analysis – Ginkgo Bioworks Intrinsic Value
GoodWhale’s analysis of GINKGO BIOWORKS fundamentals has revealed a fair value of around $4.0 per share. This fair value has been calculated using our proprietary Valuation Line, which takes into account a variety of factors such as earnings growth, profitability, and industry trends. At the current trading price of $1.3 per share, GINKGO BIOWORKS stock is undervalued by 67.2%. This means that investors may be able to capitalize on the potential upside in GINKGO BIOWORKS’ stock price as the company continues to grow and reach its full potential. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks, a US-based biotechnology company, has announced a strategic investment from Synplogen Co., Ltd, to bring its gene therapy services to Japan. The investment will finance new gene therapy research and development, as well as help Ginkgo Bioworks expand its presence in Asia. It will also help the company launch new products in Japan, including its gene therapy platform, gene editing tools, and other gene-based technologies. Ginkgo Bioworks’ CEO and Co-founder, Jason Kelly, stated that the investment from Synplogen “will enable Ginkgo to make a major impact in the field of gene therapy” in Japan.
He believes that the collaboration between both companies will allow them to bring innovative therapies to the country and help improve the lives of those affected by genetic diseases. As part of the agreement, Synplogen will provide Ginkgo Bioworks with significant resources to expand its technology and product portfolio in Japan. This could open the door to a range of new treatments for those living with genetic disorders.
